Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection and reactivation. In the current study, recipients of allogeneic HSCT (34 females, 45 males) were vaccinated with...

Full description

Bibliographic Details
Main Authors: Michael Koldehoff, Peter A. Horn, Monika Lindemann
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Vaccines
Subjects:
varicella-zoster virus
vaccination
ELISpot
hematopoietic stem cell transplantation
shingles
sex-dependency
Online Access:https://www.mdpi.com/2076-393X/10/5/809

Internet

https://www.mdpi.com/2076-393X/10/5/809

Similar Items